Core Viewpoint - The company,药捷安康-B (02617), has been selected to be included in various Hang Seng Index series components, effective from September 8, 2025, indicating increased investor recognition [1] Group 1: Index Inclusion - The company will be included in the Hang Seng Composite Index [1] - The company will also be part of the Hang Seng Composite Industry Index - Healthcare [1] - Additional indices include the Hang Seng Composite Small Cap Index and the Hang Seng Healthcare Index [1] Group 2: Investor Recognition - Inclusion in the Hang Seng Composite Index and other indices reflects a rise in investor recognition [1] - The company is also set to be part of the Hang Seng Innovation Drug Index and the Hang Seng Hong Kong Stock Connect Innovation Drug Index [1] - The company will be included in the Hang Seng Hong Kong Stock Connect Drug and Biotechnology (Investable) Index [1]
药捷安康-B获纳入恒生指数系列成份股